Curis, Inc. is a biotechnology company focused on the development of first-in-class and innovative therapeutics for the treatment of cancer.
Curis, Inc. Has Three Drug Candidates in Development: Emavusertib (CA-4948), an orally-available, small molecule inhibitor of the IRAK4 kinase.
CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation.
Fimepinostat, an orally available, small molecule inhibitor of HDAC and PI3K enzymes.
Curis, Inc. Is in Collaboration With Aurigene: Curis is engaged in a collaboration with Aurigene for discovery and development of drug candidates in the area of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule dual antagonists of PD1 and VISTA, including PDL1/VISTA antagonist CA-170, and oral small molecule dual antagonists of PD1 and TIM3, including PDL1/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948.
Collaborators at Curis: The Company's collaborators, F. Hoffmann-La Roche Ltd, or Roche, and Genentech Inc., or Genentech, a member of the Roche Group, are commercializing Erivedge®(vismodegib) for the treatment of patients with advanced basal cell carcinoma, or BCC.
The Curis Mission: Working relentlessly to develop innovative and differentiated therapeutics that improve the lives of cancer patients.
Industry: Business & Industrial > Pharmaceuticals & Biotech
More information about Curis
|Address||StreetAddress: 128 Spring St Ste 500, AddressLocality: Lexington, AddressRegion: Massachusetts, PostalCode: 2421, AddressCountry: United States|
|Number Of Employees||42|
|Ticker Symbol||NASDAQ: CRIS|
New York City, US
18 Sep 2023